Cannformatics published the results of a study on autism spectrum disorders identifying cannabis-responsive biomarkers in children.
This is the first study Examining saliva in children with autism spectrum disorders (ASD) treated with various cannabis or CBD products. This study establishes a cannabis response biomarker as a universal measure of the effects of cannabis.
It demonstrates the potential of these biomarkers as a powerful tool for quantifying at metabolic levels, the success of medical cannabis treatment for children with ASD.
This study was published in the journal Cannabis and Cannabinoid Research. Participants in the study were racially, ethnically, and socio-economically diverse and consisted of boys and girls between the ages of 6 and 12.
They were evaluated by an interdisciplinary team of experts in the biochemistry, bioinformatics, pediatrics, data science, integrated oncology, emergency medicine, and medical cannabis industries.
Children followed a unique regimen determined by their response to medical cannabis for at least one year prior to the start of the study.With cannabis CBD The product was provided by a California pharmacy in the form of tinctures and edibles.
They were divided into two groups, with 60% of children receiving CBD-dominated cannabis, followed by 40% receiving THC-dominated cannabis.
Autism Spectrum Disorder (ASD)
ASD is a developmental disorder that affects a person’s ability to communicate and interact with the world.The Autism Association It is estimated that 1 in 100 people are in the autism spectrum and there are 700,000 adults and children in the UK. People with autism may find it difficult to interact socially while suffering from extreme anxiety, hypersensitivity to light and sound, and repetitive behaviors, and they have a very focused hobby or interest. There may be. Each person with ASD is different.
ASD and cannabis
The results also show how cannabis-reactive biomarkers can be used to provide insights into improving cannabis treatment. ADHD Not only other neuropathy.
Cannformatics Is a biotechnology starter focused on personalizing medical cannabis treatment through the identification of saliva-based cannabis-reactive biomarkers. The company is currently researching medical cannabis treatments for chronic neuropathic pain.
Itzhak Kurek, PhD, Cannformatics CEO, co-founder Said:
“One of our main goals was to scientifically validate cannabis-responsive biomarkers as a universal measure for assessing the effects of cannabis. The publication of this article sets that goal. Represents more than three years of research to achieve and develop biomarker technology to objectively determine the impact of over-the-counter medical cannabis products.
Based on the strong findings from this study, we are expanding platform development to include chronic neuropathic pain, anxiety, chemotherapy-induced nausea and vomiting. “
Donald Abrams, MD, Research Co-author, Cannformatics Science Advisor comment, “This study shows that saliva-based cannabis-responsive biomarkers may be an effective tool for clinicians and researchers to use in assessing the effects of medical cannabis. It opens up new avenues in medical cannabis research and undoubtedly helps patients and their doctors to have more informed conversations about the potential role of medical cannabis in managing symptoms. “
“As a medical cannabis clinician and pediatrician treating many autistic patients, this study is very exciting. Positive results from medical cannabis can be confirmed and quantified with cannabis-responsive biomarkers. The changes seen in these biomarker levels in response to medical cannabis treatment help clinicians and parents optimize the treatment of children with autism, “Cannformatics clinical advisor said. Dr. Bonni Goldstein said.
68% of Patients with Inflammatory Bowel Disease (IBD) See Improvement With Cannabis-Study
Source link 68% of Patients with Inflammatory Bowel Disease (IBD) See Improvement With Cannabis-Study